#immunotherapy

#immunotherapy

Early detection and testing for lymphoma can lead to better outcomes.

Emotional support is crucial for those suffering from illness.

In-depth reporting on political dynamics and medical advancements engaged readers in 2024.

HERVolution secures $11.7 million Series A funding to advance HERV-targeting immunotherapies.

Citryll has raised €85M in Series B funding for its innovative therapy targeting Neutrophil Extracellular Traps (NETs) in inflammatory diseases.

Immunotherapy represents a revolutionary advancement in cancer treatment, surpassing traditional methods like chemotherapy and radiotherapy in efficacy.

B-cell therapy may offer a new, promising approach to treating glioblastoma.

Pembrolizumab nearly doubles cancer-free duration post-invasive bladder surgery, offering a crucial treatment option for high-risk patients.

Combining checkpoint inhibitors with targeted drugs like JAK inhibitors enhances immune system response in resistant cancer cases.

Breast cancer vaccines are in development, focusing on treating advanced cases and possibly preventing recurrence.

Immunotherapy has significantly improved prognosis and survival rates for patients with metastatic melanoma over the past 15 years.

The discovery of PD-1 has revolutionized cancer treatment through immunotherapy, but resistance remains a challenge.

The author's diagnosis led to a significant life change, focusing on health and cancer research.

Using a novel drug to target the STING pathway in glioblastoma reprograms immune responses, offering a promising therapeutic strategy for non-responsive patients.

Lumicks has secured €20mn funding to enhance immunotherapy drug discovery by improving its real-time cell avidity analyser technology.

Discovery of HDAC3's role in regulating immune response to KRAS-driven lung cancer indicates potential for new therapeutic approaches.

Combination immunotherapy shows promise in treating anaplastic thyroid carcinoma, a rare and aggressive form of thyroid cancer, with a response rate of 30%.

Cancer vaccines are personalized treatments designed to help the patient's immune system recognize and eliminate cancer cells.

The world's first mRNA lung cancer vaccine, BNT116, shows promise in treating non-small cell lung cancer and improving survival rates.

Natural killer (NK) cells from umbilical-cord blood show promise as a potentially effective and less side-effect-prone alternative to T-cell therapies for blood cancer treatment.

Immunotherapy combined with chemotherapy and surgery significantly improves survival in muscle-invasive bladder cancer patients compared to chemotherapy alone.

Immunosuppressants and immunotherapy alone may not prevent organ rejection in kidney transplant recipients with skin cancer.

Transplant recipients face higher risk for skin cancer and limited treatment options due to potential rejection from traditional therapies.

Daily immunotherapy via dermal patch reduced risks in children with cow's milk allergy.

Asymmetric cell division in CARTs influences their functional divergence and has implications for improving CAR T-cell therapy efficacy.

A new experimental therapeutic vaccine shows promise for people with KRAS-mutated pancreatic or colorectal cancer.

The vaccine delivers tumor-targeting molecules directly into the lymph nodes, activating T cells and showing positive results in a phase 1 trial.

Senescent cells are damaged cells that accumulate in the body and contribute to age-related diseases.

Researchers have genetically engineered T cells to target and eliminate senescent cells, resulting in rejuvenation in aged mice and slower aging in young mice.

Combination therapy of pembrolizumab chemotherapy and oncolytic adenovirus shows promise for immunotherapy-resistant non-muscle-invasive bladder cancer.

Targeting TIM3 protein may enhance survival in pediatric brain cancer treatments, specifically low-grade astrocytoma, presenting a potential new therapeutic option.

CAR-T-cell therapy faces FDA investigation for potential link to lymphomas.

CAR-T cell therapy revolutionizes blood cancer treatment by enhancing T-lymphocytes to combat tumors, with potential for wider application beyond hematological cancers.